 |
|
|
 |
Corrections Kalden JR, Scott DL, Smolen JS, et al, for the European Leflunomide Study Group. Improved functional ability in patients with rheumatoid arthritis — longterm treatment with leflunomide versus sulfasalazine. J Rheumatol 2001;28:1983-91. Table 2, bottom line: the percentage of change over an observation period of 0-24 months should be 59% and 39% for leflunomide and sulfasalazine, respectively, rather than 56% and 45%. Discussion section, left column, page 1990: "...mean HAQ scores were significantly improved with leflunomide compared with sulfasalazine at 24 months (-0.65 vs -0.60; p < 0.0149)": the values in parentheses should be (-0.65 vs -0.36; p = 0.0149). The value for change in HAQ score from baseline at 24 months in leflunomide cohorts should be 59% (not 56%), and for completers the value should be 59% (not 60%). We regret the error. Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 2001;28:1862-6. The title should read "Total hip arthroplasty in ankylosing spondylitis: outcome in 340 hips". We regret the error. |